Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort
- PMID: 17681162
- DOI: 10.1053/j.gastro.2007.05.051
Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort
Abstract
Background and aims: Mucosal healing (MH) in inflammatory bowel disease may be an important sign of efficacy of treatment and a prognostic marker of long-term disease. The aim of the study was to examine both the possible predictors of mucosal healing and the impact of healing on subsequent course of disease.
Methods: In 740 incident patients diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) between 1990 and 1994 (before biologic therapy was available), demographics and symptoms were recorded. Clinical and endoscopic evaluations were done at baseline before treatment and repeated after 1 and 5 years in 495 patients.
Results: In UC patients, education longer than 12 years and extensive disease at diagnosis were significant predictors of MH after 1 year (adjusted P = .004 and P = .02, respectively). MH was significantly associated with a low risk of future colectomy (P = .02). In patients with CD, fever at diagnosis and medical treatment without steroids were significant predictors for MH (adjusted P = .03 and P = .01, respectively). MH was significantly associated with less inflammation after 5 years (P = .02), decreased future steroid treatment (P = .02).
Conclusions: Several factors predicted subsequent MH. Education as predictor may implicate the importance of coping, compliance, or lifestyle. MH after 1 year of treatment is predictive of reduced subsequent disease activity and decreased need for active treatment. The present results give further strength to the use of mucosal healing as a clinical indicator and treatment goal in inflammatory bowel disease.
Comment in
-
Does mucosal healing impact patient outcomes long-term?Inflamm Bowel Dis. 2008 Apr;14(4):577-8. doi: 10.1002/ibd.20351. Inflamm Bowel Dis. 2008. PMID: 18240284 No abstract available.
-
Mucosal healing in inflammatory bowel disease.Rev Gastroenterol Disord. 2008 Fall;8(4):271-2. Rev Gastroenterol Disord. 2008. PMID: 19107101 No abstract available.
Similar articles
-
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.Gastroenterology. 2011 Oct;141(4):1194-201. doi: 10.1053/j.gastro.2011.06.054. Epub 2011 Jun 30. Gastroenterology. 2011. PMID: 21723220 Clinical Trial.
-
Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis.Eur J Gastroenterol Hepatol. 2010 Jul;22(7):872-9. doi: 10.1097/MEG.0b013e32833036d9. Eur J Gastroenterol Hepatol. 2010. PMID: 19648821
-
A review of infliximab use in ulcerative colitis.Clin Ther. 2008 Feb;30(2):223-30. doi: 10.1016/j.clinthera.2008.02.014. Clin Ther. 2008. PMID: 18343261 Review.
-
Mucosal healing: impact on the natural course or therapeutic strategies.Dig Dis. 2009;27(4):470-5. doi: 10.1159/000233285. Epub 2009 Nov 4. Dig Dis. 2009. PMID: 19897962 Review.
-
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.Gastroenterology. 2010 Feb;138(2):463-8; quiz e10-1. doi: 10.1053/j.gastro.2009.09.056. Epub 2009 Oct 8. Gastroenterology. 2010. PMID: 19818785
Cited by
-
Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy.J Crohns Colitis. 2021 Sep 25;15(9):1431-1442. doi: 10.1093/ecco-jcc/jjab050. J Crohns Colitis. 2021. PMID: 33730756 Free PMC article. Review.
-
Comparison of Serum Concentrations of Ustekinumab Obtained by Three Commercial Assays in Patients with Crohn's Disease.J Can Assoc Gastroenterol. 2020 Mar 31;4(2):73-77. doi: 10.1093/jcag/gwaa003. eCollection 2021 Apr. J Can Assoc Gastroenterol. 2020. PMID: 33855264 Free PMC article.
-
Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis.Fibrogenesis Tissue Repair. 2012 Oct 14;5(1):18. doi: 10.1186/1755-1536-5-18. Fibrogenesis Tissue Repair. 2012. PMID: 23062310 Free PMC article.
-
Is the disease course predictable in inflammatory bowel diseases?World J Gastroenterol. 2010 Jun 7;16(21):2591-9. doi: 10.3748/wjg.v16.i21.2591. World J Gastroenterol. 2010. PMID: 20518079 Free PMC article.
-
Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.World J Gastroenterol. 2018 Oct 14;24(38):4384-4392. doi: 10.3748/wjg.v24.i38.4384. World J Gastroenterol. 2018. PMID: 30344422 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical